Targeted α particle immunotherapy for myeloid leukemia

Blood

Volumn 100, Issue 4, 2002, Pages 1233-1239

  Jurcic, Joseph G ^a,b,c,d   Larson, Steven M ^a,b,c   Sgouros, George ^a,b,c   McDevitt, Michael R ^a,b,c   Finn, Ronald D ^a,b,c   Divgi, Chaitanya R ^a,b,c   Ballangrud, Åse M ^a,b,c   Hamacher, Klaus A ^a,b,c   Ma, Dangshe ^a,b,c   Humm, John L ^a,b,c   Brechbiel, Martin W ^a,b,c   Molinet, Roger ^a,b,c   Scheinberg, David A ^a,b,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c JOINT RESEARCH CENTRE   (Italy)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH 213; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HUM195; MONOCLONAL ANTIBODY HUM195 BI 213; UNCLASSIFIED DRUG; YTTRIUM 90;

ADULT; AGED; ALPHA RADIATION; ARTICLE; BONE MARROW CELL; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG INDICATION; DRUG POTENCY; DRUG TOLERABILITY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOREACTIVITY; ISOTOPE LABELING; MALE; MYELOID LEUKEMIA; NEUTROPENIA; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE; RADIOIMMUNOTHERAPY; THROMBOCYTE COUNT;

EID: 0037103293     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v100.4.1233.h81602001233_1233_1239     Document Type: Article

References (45)

1. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
2. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia: European study group of CAMPATH-1H treatment in chronic lymphocytic leukemia
3. Efficacy and safety of gemtuzumab ozogamicin in patients with CD 33-positive acute myeloid leukemia in first relapse
4. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia
5. Radioimmunotherapy with iodine 131 tositumomab for relapsed or refractory B-cell non-Hodgkin's lymphoma: Updated results and long-term follow-up of the University of Michigan experience
6. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue
7. Phase 1/11 trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma
8. 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome
9. Radioimmunotherapy with alpha-emitting nuclides
10. Cellular kinetics, dosimetry, and radiobiology of α-particle radioimmunotherapy: Induction of apoptosis
11. Effective alpha-particle-mediated radioimmunotherapy of murine leukemia
12. 212Bi-anti-Tac
13. Radioimmunotherapy of neoplastic meningitis in rats using an α-particle-emitting immunoconjugate
14. 213Bi
15. 213Bi]J591) for radio immunotherapy of prostate cancer
16. Radioimmunoconjugates for targeted α therapy of malignant melanoma
17. Chimeric and humanized antibodies with specificity for the CD33 antigen
18. Heterogeneity of clonogenic cells in acute myeloblastic leukemia
19. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells
20. The L4F3 antigen is expressed by unipotent colony-forming cells but not by their precursors
21. A phase IB trial of humanized antibody M195 (anti-CD33) in myeloid leukemia: Specific targeting without immunogenicity
22. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia
23. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia
24. Humanized monoclonal anti-CD33 antibody HuM195 in the treatment of relapsed/refractory acute myelogenous leukemia: Preliminary report of a phase II study
25. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias
26. Potential for myeloablation with yttrium-90-HuM195 (anti-CD33) in myeloid leukemia
27. Radiolabeled anti-CD33 monoclonal antibody M 195 for myeloid leukemias
28. 213Bi-labeled antibody constructs for clinical use
29. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity, and chemistry
30. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195
31. Monoclonal antibody M195: A diagnostic marker for acute myelogenous leukemia
32. Biological and immunological feature of humanized M195 (anti-CD33) monoclonal antibodies
33. Synthesis of C-functionalized transcyclohexyldiethylenetriaminepentaacetic acids for labeling of monoclonal antibodies with the bismuth-212 α-particle emitter
34. A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies
35. Radiometal labeling of immunoproteins: Covalent linkage of 2-(4-isothiocyanatobenzyl) diethylenetriaminepentaacetic acid ligand to immunoglobulin
36. Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates
37. Refinements and improvements for Bi-213 production and use as a targeted therapeutic radiopharmaceutical
38. 213Bi generator system for therapeutic clinical applications: Construction and operation
39. 213Bi-HuM195 (anti-CD33) in patients with leukemia
40. Radiobiology of alpha particles, III: Cell inactivation by alpha-particle traversal of the cell nucleus
41. Radioimmunotherapy with alpha-particle emitters: Microdosimetry of cells with a heterogeneous antigen expression and with various diameters of cells and nuclei
42. α-Particle emitters in radioimmunotherapy: New and welcome challenges to medical internal dosimetry
43. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide
44. Tumor therapy with targeted atomic nanogenerators